Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Ras inhibitors and related small GTPase modulators act on KRAS and on the Rac, Rho and Cdc42 proteins. Small GTPases of the Ras superfamily work as molecular switches. They cycle between an active form bound to guanosine triphosphate (GTP) and an inactive form bound to guanosine diphosphate (GDP). Oncogenic KRAS mutations such as G12C keep the protein in its signaling state. ARS-853 and KRas G12C inhibitor 4 target the mutant cysteine of KRAS G12C, while Kobe2602 interferes with binding of Ras to Raf. Salirasib, a farnesylcysteine mimetic, disrupts the membrane association of Ras. Rho-family tools include NSC 23766 and EHT 1864, which inhibit Rac, and CASIN, which targets Cdc42.
KRAS G12D modulator-1 is an effective modulator targeting the KRAS G12D mutation. It exhibits potent activity with IC50 values ranging from 1 to 10 μM against NEA-G12D, PPI-G12D, and phosphorylated ERK in AGS cells. This compound is suitable for research applications focused on cancer biology and the modulation of KRAS signaling pathways.
Out of stock
All 3 sizes
Ras Modulator-1 is a selective modulator of the Ras protein, which plays a critical role in cell signaling pathways associated with growth and differentiation. This compound has been shown to influence the activity of Ras, making it a valuable tool for investigating cancer biology and therapeutic interventions targeting Ras-driven malignancies. Research applications include studying signal transduction mechanisms and evaluating potential treatments in oncogenic signaling pathways.
JH530 is a potent inducer of methuosis, specifically targeting triple-negative breast cancer (TNBC) cells. It triggers extensive intracellular vacuolization, leading to the inhibition of TNBC cell proliferation. With its demonstrated anti-tumor activity, JH530 serves as a valuable tool for cancer research applications.
(R)-ACBI-4 is a selective PROTAC degrader targeting the GTP-loaded active state of KRAS (KRAS(on)). It exhibits notable anti-proliferative activity and effectively degrades various KRAS mutants, including KRASG12R, in cancer cell lines. This compound is utilized in research focused on understanding KRAS-driven oncogenesis and therapeutic interventions in KRAS-related cancers.
Out of stock
All 3 sizes
ZCL279 is a small molecule modulator that selectively inhibits the interaction between Cdc42 and intersectin (ITSN). At lower concentrations (
LZTR1-KRAS modulator 1 is designed to modulate the interaction between KRAS and LZTR1, thereby enhancing the recruitment of the LZTR1-KRAS complex. This compound is crucial for studies investigating the regulation of KRAS signaling pathways and their implications in cellular processes. Its application can further elucidate the role of LZTR1 in cancer biology and potential therapeutic interventions targeting KRAS-driven tumors.
(+)-Oxanthromicin is a K-Ras localization modulator that disrupts the localization of oncogenic mutant K-Ras from the plasma membrane in intact Madin-Darby canine kidney (MDCK) cells. This compound demonstrates significant antitumor efficacy, making it valuable for research into cancer biology and potential therapeutic strategies targeting K-Ras-mediated signaling pathways. Its ability to alter K-Ras localization positions it as a promising candidate in the development of targeted cancer therapies.
Sp-8-Br-2'-O-Me-cAMPS is a cAMP analog that serves as a potent activator of the exchange protein directly activated by cyclic AMP (EPAC). This compound is valuable for studying the role of EPAC in various biological pathways, particularly those related to metabolism. Its ability to modulate EPAC activity makes it an important tool for investigating signaling mechanisms and their implications in metabolic processes.
Goralatide is a Ra activator that modulates the thermal sensitivity of hematopoietic progenitor cells. It enhances the disparity in thermal sensitivity between leukemia progenitor cells and normal hematopoietic progenitor cells, thereby increasing the efficacy of hyperthermia therapy. This compound is relevant for research in cancer treatment strategies, particularly those involving targeted thermal therapies.
Sp-8-pCPT-2'-O-Me-cAMPS is a selective activator of the exchange protein directly activated by cyclic AMP (EPAC). This compound enhances EPAC-mediated signaling pathways, playing a significant role in the regulation of various physiological processes. It is valuable for research into endocrine metabolism and related signaling mechanisms.
Out of stock
All 3 sizes
2-AHA-cAMP is a cAMP analogue that acts as an activator of cAMP-dependent protein kinase. The molecule features a free terminal primary amino group, enabling its coupling to gels or fluorescent dyes for enhanced experimental versatility. Its application extends to various research areas including signaling pathways and protein interaction studies, making it a valuable reagent for biophysical and biochemical investigations.
Out of stock
All 3 sizes